Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. 1993

G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
Department of Medicine, University of Innsbruck, Austria.

In 16 members of two Austrian families affected by a missense mutation at codon 188 of the lipoprotein lipase (LPL) gene (8 heterozygous and 8 normal subjects), carrier status for the mutation as determined by DNA analysis was related to LPL activity in postheparin plasma, to the magnitude of postprandial lipemia, and to concentration, composition, and size of the major lipoprotein classes of postabsorptive plasma. Carriers exhibited clearly reduced LPL activity, normal fasting triglycerides, but pronounced postprandial lipemia. The carriers' impaired triglyceride tolerance, as evident in the postprandial state of challenge only, was associated with a fasting lipoprotein constellation characterized by (a) enrichment of HDL2 with triglycerides, (b) reduced HDL2-cholesterol, (c) enrichment of VLDL and intermediate density lipoprotein (IDL) with cholesteryl esters, (d) elevated IDL levels, and (e) small-sized LDL. Within any given individual, the degrees of expression of these characteristics were quantitatively and continuously related with each other as well as with the magnitude of lipemia and with LPL activity.

UI MeSH Term Description Entries
D008071 Lipoprotein Lipase An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinemia Type I. (Dorland, 27th ed) EC 3.1.1.34. Heparin-Clearing Factor,Lipemia-Clearing Factor,Diacylglycerol Lipase,Diglyceride Lipase,Post-Heparin Lipase,Postheparin Lipase,Postheparin Lipoprotein Lipase,Factor, Heparin-Clearing,Factor, Lipemia-Clearing,Heparin Clearing Factor,Lipase, Diacylglycerol,Lipase, Diglyceride,Lipase, Lipoprotein,Lipase, Post-Heparin,Lipase, Postheparin,Lipase, Postheparin Lipoprotein,Lipemia Clearing Factor,Lipoprotein Lipase, Postheparin,Post Heparin Lipase
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated

Related Publications

G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
September 1985, Metabolism: clinical and experimental,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
September 1990, The Journal of clinical investigation,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
May 1992, Journal of lipid research,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
March 2002, Diabetologia,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
September 1990, The Journal of clinical investigation,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
April 1990, The Journal of biological chemistry,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
December 1994, Journal of lipid research,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
January 2005, Journal of inherited metabolic disease,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
January 2013, Journal of clinical lipidology,
G Miesenböck, and B Hölzl, and B Föger, and E Brandstätter, and B Paulweber, and F Sandhofer, and J R Patsch
February 1999, American journal of human genetics,
Copied contents to your clipboard!